Total Payments
$18,834
2022 Payments
$143.94
Companies
18
Transactions
43
Payment Breakdown by Category
Other$8,384 (44.5%)
Consulting$5,800 (30.8%)
Research$3,965 (21.1%)
Food & Beverage$684.14 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,384 | 6 | 44.5% |
| Consulting Fee | $5,800 | 2 | 30.8% |
| Unspecified | $3,965 | 2 | 21.1% |
| Food and Beverage | $684.14 | 33 | 3.6% |
Payments by Type
General
$14,869
41 transactions
Research
$3,965
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11,038 | 5 | $0 (2017) |
| F. Hoffmann-La Roche AG | $7,130 | 6 | $0 (2019) |
| Amgen Inc. | $150.04 | 4 | $0 (2017) |
| Genentech, Inc. | $143.94 | 1 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $83.72 | 6 | $0 (2017) |
| Genentech USA, Inc. | $74.64 | 6 | $0 (2017) |
| PFIZER INC. | $46.93 | 4 | $0 (2017) |
| Bayer HealthCare Pharmaceuticals Inc. | $19.91 | 1 | $0 (2017) |
| Heron Therapeutics, Inc. | $19.89 | 1 | $0 (2017) |
| Janssen Research & Development, LLC | $17.97 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $143.94 | 1 | Genentech, Inc. ($143.94) |
| 2019 | $1,919 | 1 | F. Hoffmann-La Roche AG ($1,919) |
| 2018 | $2,060 | 2 | F. Hoffmann-La Roche AG ($2,047) |
| 2017 | $14,711 | 39 | Novartis Pharmaceuticals Corporation ($11,038) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/05/2022 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $143.94 | General |
| 06/30/2019 | F. Hoffmann-La Roche AG | Zelboraf (Biological) | — | In-kind items and services | $1,918.75 | Research |
| Study: A PHASE 1B, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED IN COMBINATION WITH VEMURAFENIB OR VEMURAFENIB PLUS COBIMETINIB IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MELANOMA • Category: BioOncology | ||||||
| 12/31/2018 | F. Hoffmann-La Roche AG | Zelboraf (Biological) | — | In-kind items and services | $2,046.67 | Research |
| Study: A PHASE I TRIAL OF VEMURAFENIB AND IPILIMUMAB IN SUBJECTS WITH V600 BRAF MUTATION-POSITIVE METASTATIC MELANOMA • Category: BioOncology | ||||||
| 04/11/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: Oncology | ||||||
| 09/28/2017 | Sysmex Inostics Inc | — | Food and Beverage | Cash or cash equivalent | $10.59 | General |
| 09/05/2017 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $17.97 | General |
| 06/30/2017 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,270.18 | General |
| Category: BioOncology | ||||||
| 06/30/2017 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,074.77 | General |
| Category: BioOncology | ||||||
| 06/30/2017 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $443.91 | General |
| Category: BioOncology | ||||||
| 06/30/2017 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $375.62 | General |
| Category: BioOncology | ||||||
| 06/15/2017 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,610.00 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2017 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,610.00 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2017 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $10.79 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2017 | Heron Therapeutics, Inc. | SUSTOL (Drug) | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: CINV | ||||||
| 06/07/2017 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: BioOncology | ||||||
| 05/23/2017 | Teva Pharmaceuticals USA, Inc. | BENDEKA (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Oncology | ||||||
| 05/22/2017 | Genentech USA, Inc. | Avastin (Biological), Tarceva, Alecensa | Food and Beverage | In-kind items and services | $11.44 | General |
| Category: BioOncology | ||||||
| 05/17/2017 | Amgen Inc. | Neulasta (Biological), Vectibix, XGEVA | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Oncology | ||||||
| 05/16/2017 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: BioOncology | ||||||
| 05/15/2017 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $11.17 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2017 | Genentech USA, Inc. | Erivedge (Biological), COTELLIC | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: BioOncology | ||||||
| 05/09/2017 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $107.17 | General |
| Category: Oncology | ||||||
| 05/03/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2017 | Merck Sharp & Dohme Corporation | EMEND (Drug), KEYTRUDA | Food and Beverage | In-kind items and services | $9.32 | General |
| Category: ONCOLOGY | ||||||
| 04/26/2017 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE I TRIAL OF VEMURAFENIB AND IPILIMUMAB IN SUBJECTS WITH V600 BRAF MUTATION-POSITIVE METASTATIC MELANOMA | F. Hoffmann-La Roche AG | $2,047 | 1 |
| A PHASE 1B, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED IN COMBINATION WITH VEMURAFENIB OR VEMURAFENIB PLUS COBIMETINIB IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MELANOMA | F. Hoffmann-La Roche AG | $1,919 | 1 |
About Dr. Jeffrey Infante, MD
Dr. Jeffrey Infante, MD is a Medical Oncology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396848271.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Infante, MD has received a total of $18,834 in payments from pharmaceutical and medical device companies, with $143.94 received in 2022. These payments were reported across 43 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($8,384).
Ad
Practice Information
- Specialty Medical Oncology
- Location Nashville, TN
- Active Since 09/06/2006
- Last Updated 01/25/2012
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1396848271
Products in Payments
- MEKINIST (Drug) $11,020
- Zelboraf (Biological) $3,965
- TECENTRIQ (Biological) $3,173
- Kyprolis (Biological) $126.08
- EMEND (Drug) $52.15
- IBRANCE (Drug) $34.50
- KEYTRUDA (Biological) $31.57
- Erivedge (Biological) $25.70
- Avastin (Biological) $24.00
- Nexavar (Drug) $19.91
- SUSTOL (Drug) $19.89
- AFINITOR (Drug) $17.70
- BENDEKA (Drug) $17.07
- Neulasta (Biological) $16.89
- Perjeta (Biological) $16.22
- Cabometyx (Drug) $15.02
- Zevalin (Drug) $14.91
- DARZALEX (Biological) $13.55
- Lonsurf (Drug) $13.42
- Abraxane (Drug) $13.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Nashville
Dana Thompson, M.d, M.D
Medical Oncology — Payments: $578,344
Medical Oncology $578,344
David Spigel, M.d, M.D
Medical Oncology — Payments: $576,692
Medical Oncology $576,692
Johanna Bendell, M.d, M.D
Medical Oncology — Payments: $430,557
Medical Oncology $430,557
Dr. Melissa Johnson, Md, MD
Medical Oncology — Payments: $361,734
Medical Oncology $361,734
Mace Rothenberg, Md, MD
Medical Oncology — Payments: $251,948
Medical Oncology $251,948
Cathy Eng, M.d, M.D
Medical Oncology — Payments: $216,319
Medical Oncology $216,319